Affiliation:
1. LLC "CPHA"
2. LLC "CPHA";
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)
3. National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)
4. LLC "CPHA";
Peoples Friendship University of Russia (RUDN University)
Abstract
Introduction. Tranexamic acid is one of the most common drugs used to stop bleeding after trauma, in surgery and gynecology. The most common analytical method for the determination of this compound is reversed-phase high-performance liquid chromatography (HPLC). However, this compound belongs to the group of so-called poorly retained compounds due to its chemical structure. It is necessary to develop an analytical method that will allow the determination of tranexamic acid in human blood plasma with the least time, resource costs and without the use of specialized columns.Aim. The aim of this study is to develop a method for tranexamic acid in human plasma by high performance liquid chromatography with tandem mass-spectrometry (HPLC-MS/MS) for pharmacokinetic studies.Materials and methods. Determination of tranexamic acid in plasma by HPLC-MS/MS. The samples were processed by acetonitrile protein precipitation.Results and discussion. This method was validated by next parameters: selectivity, matrix effect, calibration curve, accuracy, precision, recovery, lower limit of quantification, carry-over effect and stability.Conclusion. The method of the determination of tranexamic acid in human plasma was developed and validated by HPLC-MS/MS. The linearity in plasma sample was achieved in the concentration range of 100.00–15000.00 ng/ml. Method could be applied to tranexamic acid determination in plasma for pharmacokinetics and bioequivalence studies.
Publisher
Center of Pharmaceutical Analytics Ltd
Subject
Drug Discovery,Pharmaceutical Science
Reference13 articles.
1. Dunn C. J., Goa K. L. Tranexamic acid. Drugs. 1999;57(6):1005–1032.
2. Ng W. Ch. K., Jerath A., Wasowicz M. Tranexamic acid: a clinical review. Anestezjologia Intensywna Terapia. 2015;47(4):339–350. DOI: 10.5603/AIT.a2015.0011.
3. Klebanoff J. S., Marfori Сh. Q., Ingraham C. F., Wu C. Z., Moawad G. M. Applications of Tranexamic acid in benign gynecology. Current Opinion in Obstetrics & Gynecology. 2019;31(4):235–239. DOI: 10.1097/GCO.0000000000000547.
4. Ogawa H., Asakura H. Consideration of tranexamic acid administration to COVID-19 patients. Physiological reviews. 2020; 100(4):1595–1596. DOI: 10.1152/physrev.00023.2020.
5. Rasporyazhenie Pravitel'stva RF ot 12 oktyabrya 2019 g. № 2406-r. "Ob utverzhdenii perechnya zhiznenno neobkhodimykh i vazhneyshikh lekarstvennykh preparatov na 2020 god, a takzhe perechney lekarstvennykh preparatov dlya meditsinskogo primeneniya i minimal'nogo assortimenta lekarstvennykh preparatov, neobkhodimykh dlya okazaniya meditsinskoy pomoshchi" [Order of the Government of the Russian Federation of 12 October 2019 No. 2406-r. "On approval of the list of vital and essential drugs for 2020, as well as lists of drugs for medical use and the minimum range of drugs required for the provision of medical care"]. Available at: https://docs.cntd.ru/document/563469457. Accessed: 12.05.2021. (In Russ.)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献